Acute treatment and medication at discharge in three different study centres in Bern (Switzerland), Gdansk (Poland) and Lutsk (Ukraine) (denominators in percentage)
| Treatment | Bern (Switzerland) | Gdansk (Poland) | Lutsk (Ukraine) | p Value for all | Bern vs Gdansk | Bern vs Lutsk | Gdansk vs Lutsk |
| Fibrinolysis | 0% (547) | 0% (375) | 30.8% (164) | <0.001 | <0.001 | <0.001 | |
| PCI | 98% (547) | 92.3% (375) | 0% (164) | <0.001 | <0.001 | <0.001 | <0.001 |
| Antiplatelet at discharge | 100% (547) | 100% (375) | 97.2% (147) | <0.001 | 0.002 | 0.006 | |
| Statin at discharge | 97.6% (547) | 97% (375) | 94.6% (147) | 0.153 | 0.602 | 0.054 | 0.169 |
| ACEIs or ARB at discharge | 89% (547) | 88% (375) | 81.6% (147) | 0.052 | 0.628 | 0.016 | 0.058 |
| β-Blocker at discharge | 87.9% (547) | 77.1% (375) | 92.5% (147) | <0.001 | <0.001 | 0.116 | <0.001 |
Comparisons between the three study centres with regard to fibrinolysis, PCI and medication.
ACEIs, ACE inhibitors; ARB, angiotensin receptor blocker; PCI, percutaneous coronary intervention.